Qube Research & Technologies (QRT)
EIGR

Qube Research & Technologies (QRT)’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-203
Closed -$1.86K – 4861
2023
Q3 		$1.86K Sell
203
-1,855
-90% -$37.3K ﹤0.01% 3577
2023
Q2 		$43.5K Buy
+2,058
New +$63.4K ﹤0.01% 2087

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Qube Research & Technologies (QRT)'s EIGR Position: Q4 2023 in Review

Qube Research & Technologies (QRT) sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2023, closing a stake of 203 shares — an estimated $1.86K sold.

Qube Research & Technologies (QRT) first reported a position in EIGR in Q2 2023 and held it in 2 quarters. The position peaked at $43.5K in Q2 2023. 43 funds tracked by Wall St. Rank hold EIGR as of Q4 2023.

  • Qube Research & Technologies (QRT) reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 203 Eiger BioPharmaceuticals, Inc. shares in Q4 2023, an estimated $1.86K.
  • Qube Research & Technologies (QRT) first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2023 and held it in 2 quarters.
  • Qube Research & Technologies (QRT)'s Eiger BioPharmaceuticals, Inc. position peaked at $43.5K in Q2 2023.
  • 43 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2023.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q4 2023, filed 13 Feb 2024.